HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation today announced that Zogenix, Inc. (“Zogenix”) and Astellas Pharma US, Inc. (“Astellas”) entered into an exclusive co-promotion agreement for the Sumavel DosePro (sumatriptan injection) needle-free delivery system. Sumavel DosePro received FDA approval in July 2009 and is a first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, a treatment that provides migraine relief within 10 minutes for some patients. Aradigm is entitled to a $4 million milestone payment upon first U.S. commercial sale, and royalty payments upon any sales of products in the U.S. and other countries, including the European Union, which may be developed and sold using the DosePro technology.
Zogenix announced that Sumavel DosePro is expected to be commercially available in January 2010. Under the terms of the co-promotion agreement, Zogenix and Astellas will collaborate on the promotion and marketing of Sumavel DosePro with Zogenix focusing their sales activities primarily on the neurology market while Astellas will focus mostly on primary care physicians.
In August 2006, Aradigm sold all of its assets related to the Intraject™ needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix, Inc., a private company. Zogenix is responsible for development and commercialization efforts of Intraject (now rebranded under the name DosePro).
About Aradigm
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, inhalation anthrax infections and smoking cessation.
More information about Aradigm can be found at www.aradigm.com.
Forward-Looking Statements
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including payments of milestones and royalties, plans for commercialization of DosePro products and the potential for sales of DosePro products, as well as the other risks detailed from time to time in Aradigm Corporation’s Securities and Exchange Commission (SEC) Filings, including the Company’s Annual Report on Form 10-K, and quarterly reports on Form 10-Q.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.
Other names and brands may be claimed as the property of others.
Contact:
Aradigm Investor Relations, 510-265-8850/9370
